Familial Hypocalciuric Hypercalcemia: Decoding the Genetic Puzzle

Expert Reviewed By: Dr. Brandon Colby MD

Familial Hypocalciuric Hypercalcemia (FHH) is a rare genetic condition characterized by elevated blood calcium levels, low urinary calcium excretion, and normal to slightly elevated parathyroid hormone levels. While it might sound daunting, advancements in genetic testing are proving to be a beacon of hope for individuals and families affected by this condition. Recent discoveries, including a novel GNA11 Thr347Ala variant, are offering new insights into the genetic underpinnings of FHH2, a subtype of this disorder.

Understanding Familial Hypocalciuric Hypercalcemia

FHH is primarily caused by mutations in the genes responsible for calcium-sensing receptor (CaSR) signaling, which plays a crucial role in maintaining calcium homeostasis in the body. When these receptors are disrupted, calcium levels in the blood can become imbalanced. The recent identification of a novel GNA11 Thr347Ala variant highlights the complexity of FHH2 and emphasizes the importance of genetic testing in understanding and managing this condition.

The Role of Genetic Testing in FHH

Genetic testing has become an invaluable tool in the diagnosis and management of hereditary conditions like FHH. By identifying specific genetic mutations, healthcare providers can offer more personalized care, tailor treatment plans, and provide genetic counseling to affected families.

Diagnosing Familial Hypocalciuric Hypercalcemia

For individuals with persistent hypercalcemia, genetic testing can confirm a diagnosis of FHH by identifying mutations in the CaSR, GNA11, or AP2S1 genes. This confirmation is crucial, as FHH is often misdiagnosed as primary hyperparathyroidism, leading to unnecessary surgical interventions. With genetic testing, healthcare providers can distinguish between these conditions and avoid inappropriate treatments.

Guiding Treatment Decisions

While FHH typically does not require treatment, understanding the genetic basis of the condition can help guide clinical decisions. For instance, individuals with FHH2, associated with the GNA11 Thr347Ala variant, may exhibit different clinical features compared to those with other FHH subtypes. Genetic testing can provide insights into the specific mutation present, allowing clinicians to monitor patients more effectively and adjust management strategies as needed.

Providing Genetic Counseling

Genetic testing not only aids in diagnosis and management but also plays a critical role in genetic counseling. Families affected by FHH can benefit from understanding the hereditary nature of the condition and the associated genetic risks. Genetic counselors can provide valuable information on the likelihood of passing the condition to offspring, enabling families to make informed decisions about family planning and healthcare.

Research and Future Directions

The discovery of the GNA11 Thr347Ala variant represents a significant advancement in our understanding of FHH2. As research continues, genetic testing will likely uncover additional variants and mutations, further unraveling the complexities of calcium homeostasis and receptor signaling. These discoveries not only enhance our understanding of FHH but also open new avenues for potential therapeutic interventions.

In conclusion, genetic testing is a powerful tool in the fight against Familial Hypocalciuric Hypercalcemia. By identifying specific genetic mutations, it offers clarity in diagnosis, guides treatment decisions, and provides essential information for genetic counseling. As research progresses, the role of genetic testing in managing FHH will undoubtedly expand, providing hope and clarity for affected individuals and their families.

For more detailed information on the novel GNA11 Thr347Ala variant and its impact on FHH2, you can access the study here: https://doi.org/10.1210/clinem/dgae440

About The Expert Reviewer

Dr. Brandon Colby MD is a US physician specializing in the personalized prevention of disease through the use of genomic technologies. He’s an expert in genetic testing, genetic analysis, and precision medicine. Dr. Colby is also the Founder of  and the author of ⁠Outsmart Your Genes.

Dr. Colby holds an MD from the Mount Sinai School of Medicine, an MBA from Stanford University’s Graduate School of Business, and a degree in Genetics with Honors from the University of Michigan. He is an Affiliate Specialist of the American College of Medical Genetics and Genomics (⁠ACMG), an Associate of the American College of Preventive Medicine (⁠ACPM), and a member of the National Society of Genetic Counselors (NSGC)